San Diego-based Aragon Pharmaceuticals, which is developing small molecule drugs to treat cancer, has raised another $50M in a Series D funding, the firm said today. The funding was led by VenBio, and also included Topspin Fund, Aisling Capital, OrbiMed Advisors and The Column Group. The firm just raised a round in March, and said it has not raised $88M in total capital during 2012; in total, it looks like the firm has now raised over $122.0M in funding for its efforts. Aragon's first target is the treatment of castration-resistant prostate cancer (CRPC). More information »